leadf
logo-loader
viewCallitas Health Inc

M Pharmaceutical’s e-Mosquito technology successfully completes milestone test

pharma_manufacturing_350_5552585f1e395.jpg
In December 2014, the company bought M Diagnostics to acquire the rights to the eMosquito technology

M Pharmaceutical (CSE:MQ) said that a human testing pilot demonstrated that a prototype of the single-cell e-Mosquito, a wearable blood glucose monitoring system designed for diabetics, using shape memory alloy (SMA) technology, successfully penetrated the skin, reaching a subcutaneous capillary to extract a minute blood sample for further in-situ glucose analysis.

"This is an exciting milestone in the development of the e-Mosquito technology and our electronically-controlled microsystem for minimally-invasive, periodic sampling of whole blood for the purpose of autonomous glucose monitoring in diabetics," said M Pharmaceuticals’ President and Chief Executive Officer, Dr. Martin Mintchev.

The test has proven that the e-Mosquito actuator, for which the company has a pending patent, is practical and feasible. It also brings the company one step closer to developing a six-cell, autonomous e-Mosquito prototype and an integrated electronic glucose analysis system.

M Pharmaceutical will also be able to perform statistically sound, comprehensive, and comparative human testing in its quest to operationalize the e-Mosquito technology, starting with pre-registration clinical trials.

In December 2014, the company bought M Diagnostics to acquire the rights to the eMosquito technology, to be developed as a less invasive way for diabetics to take blood samples for glucose level checks, by penetrating the skin to shallower depths, in less sensitive areas of the body.

Typically, diabetics prick their fingers to monitor their blood glucose levels, which can be painful. The eMosquito, however, is designed to be worn like a patch, with small needles to puncture the skin just deep enough to draw blood without damaging any nerves, causing little or no pain at all.

The idea is to have a cuff-based device that automatically draws whole blood samples and monitors blood sugar levels on a regular basis. The medical product is composed of at least six single-use needles that "bite" sequentially at pre-programmed levels.

A commercial strip-based sensor associated with each needle will then measure glucose levels, with the data to be sent wirelessly to a remote device such as a smartphone. The patient need only replace the needles and the strips once every day.

The International Diabetes Federation (IDF) expects the number of people living with diabetes to rise from 387 million in 2014 to 592 million by 2035, which will dramatically increase global demand for treatment and control of the disease.

Quick facts: Callitas Health Inc

Price: - CAD

CSE:LILY
Market: CSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment pleased Canada taking a look at allowing single...

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news the company is hailing the Canadian government’s decision to introduce legislation that would legalize single-event sports betting in Canada. Eghdami talks about why that...

1 day, 8 hours ago

2 min read